Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
Study Details
Study Description
Brief Summary
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of Avatrombopag combined with IST in very/sever aplastic anemia patients with abnormal liver function or HAAA patients treated for the first time. The design was: Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. Cyclosporine 3 mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy, and Avatrombopag, which was administered in the dose of 40 mg orally once daily for a total of 12 weeks. Thirty-nine patients are expected to be enrolled in this study. Evaluation endpoint: complete response rate at 12 weeks of treatment.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
This is a multicenter, single-arm clinical study to evaluate the efficacy and safety of Avatrombopag combined with IST as the first-line regimen for aplastic anemia. The patients are diagnosed as hepatitis associated with very sever/sever aplastic anemia(V/SAA) or V/SAA with abnormal liver function before treatment.
Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: 40 mg orally once daily for a total of 12 weeks. A total of 39 patients were expected to be included.Complete response rate at 12 weeks of treatment and adverse events are the evaluation endpoint.Secondary study endpoints were: ORR at 12 , CRR and ORR at 24 weeks, survival, and clonal evolution in follow-up.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Avatrombopag+CsA+ p-ATG Patients received p-ATG for 5 consecutive days (day 1-5), at a dose of 20 mg/kg/day. CSA is started at 3 mg/kg orally in two doses. Concentrations maintained at 200-250 ng/ml to achieve maximum efficacy and then tapered by 25 mg every 3 months; Avatrombopag: 40 mg orally once daily for a total of 12 weeks. A total of 39 patients were expected to be included. |
Drug: Avatrombopag 20 MG Oral Tablet
p-ATG and CsA in combination with Avatrombopag to treat
Other Names:
|
Outcome Measures
Primary Outcome Measures
- CR rate at 12 weeks of treatment [12 weeks of treatment]
Percentage of the total number of patients receiving treatment who received a complete response at 12 weeks of treatment
- ncidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 12 weeks of treatment [12 weeks of treatment]
Incidence of Treatment-Emergent AE by CTCAE
Secondary Outcome Measures
- OR rate at 12 weeks of treatment [12 weeks of treatment]
Percentage of the total number of patients receiving treatment who received a response at 12 weeks of treatment
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patients with V/SAA with a definite diagnosis.
-
age between 18-70 years, male or female.
-
Subjects must complete all screening assessments as outlined in the trial protocol.
-
Able to swallow or administer the drug orally.
-
No prior application of TPO receptor agonists (including Thrombopoietin, Eltrombopag, Hetrombopag, etc.) or application of TPO receptor agonists for treatment with ≤ 5 total doses and ≤ 7 days of TPO receptor agonist drugs such as Eltrombopag, Hetrombopag, etc.
-
Diagnosis as HAAA or abnormal liver function. ALT and AST more than 1.5 times of upper limit.
-
Informed consent must be signed prior to the start of all specific study procedures, in consideration of the patient's condition, or by a member of the patient's immediate family if the patient's signature is not conducive to the treatment of the condition.
Exclusion Criteria:
-
Known diagnosis of congenital hematopoietic failure disorders (e.g. Fanconi anemia) and other causes of allogeneic cytopenias and bone marrow hypoproliferative disorders (e.g. hemolytic PNH, hypoproliferative MDS/AML, autoantibody-mediated allogeneic cytopenias, etc.);
-
Patients with uncontrolled bleeding and/or infection despite standard treatment.
-
Patients with previous history of hematopoietic stem cell transplantation; previous history of thrombosis.
-
Patients with concurrent malignancy or potential cancer on immunosuppressive therapy.
-
Those who are considered unsuitable for enrollment by the investigator.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin | Tianjin | China | 300020 |
Sponsors and Collaborators
- Institute of Hematology & Blood Diseases Hospital
Investigators
- Study Director: Wenrui Yang, Anemia Therapeutic center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IIT2021008-EC-1(2)